You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新股IPO:創新藥企百利天恒登陸港股

百利天恒藥業股份有限公司(Sichuan Biokin Pharmaceutical Co., Ltd., 2615.HK)啟動香港IPO,招股期為11月7日至11月12日,擬全球發售8,634,300股H股,並設重新分配機制;每股發售價介乎347.50–389.00港元,每手100股,入場費約39,292.31港元;預期11月17日於聯交所主板掛牌,聯席保薦人為高盛、J.P. Morgan及中信證券。

百利天恒:具備研發與商業化能力的綜合醫藥企業

發行比例:香港公開發售約10%(863,500股H股,可重新分配),國際配售約90%(7,770,800股H股,可重新分配)。

發行價格:347.50–389.00港元;每手100股;入場費約39,292.31港元。

發行日期:11月7日至11月12日(預期定價日11月13日)。

上市日期:11月17日。

IPO 保薦人:高盛、J.P. Morgan、中信證券。

 

公司簡介

百利天恒是一傢俱備早期研發、臨床開發、生產及商業化能力的綜合醫藥企業集團,業務涵蓋創新生物藥及仿製藥與中成藥的研發與銷售。公司擁有全球首創且唯一進入臨床III期階段的EGFR×HER3雙特異性抗體ADC藥物iza-bren,並於2023年12月與BMS達成總對價最高84億美元的戰略合作。公司通過超過1,000家經銷商覆蓋中國30多個省份的醫院及藥房。

 

財務資訊

招股檔披露,百利天恒於2022–2024年收入分別約7.02億元、5.60億元及58.21億元(人民幣),同期淨利潤分別虧損2.82億元、虧損7.81億元及盈利37.08億元;2025年第一季度收入約1.70億元、淨虧損約11.18億元。按中位價368.25港元計,公司預計募資淨額約30.18億港元,資金擬用於中國內地以外候選生物藥物的研發(約60%)、建立全球供應鏈(約30%)及營運資金與一般公司用途(約10%)。

 

uSMART 推出「港股 IPO 費用豁免優惠」,幫您 0 成本認購新股

融資認購 0 息*,10 倍杠杆

現金認購 0 手續費

支持暗盤交易

*融資認購金額 1,000 萬港元或以下免利息。^現金認購免手續費。此推廣優惠於 2025 年 5 月 20 日起至另行通知,部分熱門新股可能不參與優惠,相關實際利息及手續費請以 uSMART App 認購頁面為准,有關政府及交易所費用仍將按規收取。本公司保留隨時更改、暫停或終止上述優惠、條款及細則的權利,而毋須另行通知客戶,並一切均以本公司之解釋為准。

如何在 uSMART HK 認購百利天恒

uSMART HK App 設有 IPO 中心,提供獨家優惠,客戶可在 App 即時認購公開發售之新股。登入 uSMART HK App 後,點選右下角「交易」,進入「新股認購」,選擇百利天恒後點擊「公開認購」,填寫認購數量並提交訂單即可。

(圖源:uSMART HK app)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account

More Content